Clinical trials
Hepatitis clinical trials
Below are recruiting hepatitis clinical trials, each written for real people, not researchers. We’re tracking 480 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07684326RecruitingPhase 2/Phase 3
Can dapagliflozin help liver cirrhosis with fluid buildup? (Phase 2/3 randomized trial)
This trial tests a diabetes pill (dapagliflozin) to see if it helps people with liver cirrhosis and fluid buildup (ascites). The goal is to improve fluid balance and possibly reduce hospital stays.
GizaAges 18 years+ - NCT07668934Enrolling by invitationPhase 4
TAF for early and middle pregnancy with chronic hepatitis B
This trial tests a hepatitis B medicine called TAF in pregnant women who need antiviral treatment. It helps protect both mom and baby from complications of the virus.
Guangzhou, GuangdongAges 20–40 - NCT05830136Recruiting
Bicarbonate fluid during laparoscopic liver surgery
This trial tests whether giving a specific salt-water fluid (sodium bicarbonate in Ringer’s solution) during laparoscopic liver surgery can improve safety or outcomes. You may be eligible if you’re an adult planning this type of minimally invasive liver operation and can provide consent.
Nanjing, JiangsuAges 18 years+ - NCT05480696RecruitingPhase 2
Soluble fiber supplement for fatty liver in kids
This Phase 2 study tests whether a soluble fiber supplement can improve fatty liver disease in children who have obesity and confirmed NAFLD. It may help reduce liver fat and related liver enzyme elevations measured during clinic visits and MRI.
Hamilton, OntarioAges 8–17 - NCT07654855Recruiting
Long-term safety of eplontersen in ATTR patients
This study follows people who already took part in an earlier trial (D8450R00003) to see how safe eplontersen is over the long term. It also includes people who had a liver transplant or severe liver problems.
Los Angeles, CaliforniaAges 18 years+ - NCT05346393Recruiting
TIPS procedure for kidney failure in people with cirrhosis
This trial studies whether a liver procedure called TIPS can help people with cirrhosis who develop sudden kidney failure (HRS-AKI). It aims to improve kidney function and overall outcomes, but participation depends on several safety checks.
AachenAges 18–80 - NCT04588077RecruitingPhase 4
Two-dose vs three-dose hepatitis B vaccine for cirrhosis
This study compares giving the hepatitis B vaccine in 2 doses versus 3 doses for people with cirrhosis who do not yet have protection against hepatitis B. It may help your care team choose the schedule most likely to build lasting immunity.
Baltimore, MarylandAges 18 years+ - NCT07636798RecruitingPhase 1/Phase 2
Chemotherapy and immunotherapy combination for advanced bile duct cancer
This trial tests a combination of three treatments—chemotherapy delivered directly to the liver, plus two immunotherapy drugs—for advanced bile duct cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment and is safe for patients.
Chengdu, SichuanAges 18–75 - NCT05484908Recruiting
Tested treatment for hepatitis B-related liver cancer after immunotherapy
This trial studies whether the ALSS treatment is safe and effective for people with hepatitis B-related hepatocellular carcinoma who recently received immune checkpoint inhibitors. It may help improve outcomes for certain liver-related complications after immunotherapy, based on how their liver tests look.
Guangzhou, GuangdongAges 18–65 - NCT03920618Recruiting
Testing three HBV medicines for severe liver flare (ACLF)
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
Guangzhou, GuangdongAges 12–65 - NCT04597164Recruiting
Test a hepatitis B–targeted treatment for serious liver failure
This trial studies a combination approach called DPMAS and low-volume plasma exchange for people with hepatitis B–related acute-on-chronic liver failure. If you qualify, the goal is to improve your liver function and reduce serious complications from liver failure.
Guangzhou, GuangdongAges 18–65 - NCT07607769Recruiting
Tremelimumab and Durvalumab for Untreated Advanced Liver Cancer
This Italian study follows patients with advanced liver cancer (hepatocellular carcinoma) who receive a combination immunotherapy treatment called STRIDE for the first time. The trial tracks how well the treatment works, how it affects quality of life, and its safety in people with moderate to severe liver disease.
AnconaAges 18–100 - NCT07610837RecruitingPhase 2
Testing AZD2389 for fatty liver disease with scarring
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Chandler, ArizonaAges 18 years+ - NCT06694012Recruiting
Ohtori Study Part 2 heart health
This study looks at heart and metabolic health in the general population. It helps researchers understand how to prevent conditions like diabetes and heart disease.
Sakai, OsakaAges 20 years+ - NCT07600788RecruitingPhase 1
Liver Function and Safety Study of AHB-137 Injection
This study tests how a new investigational drug called AHB-137 moves through your body and affects safety in people with mild-to-moderate liver problems compared to people with normal liver function. The goal is to understand if the drug works safely in people whose livers don't work as well as they should.
Chongqing, Chongqing MunicipalityAges 18–65 - NCT06718530Recruiting
Finding early markers for liver cancer in people with chronic liver disease
This study looks for substances in your blood and immune system that could help doctors find liver cancer earlier. It is for people with liver cancer caused by chronic liver problems like hepatitis C, cirrhosis, or scarring.
Aviano, PordenoneAges 18 years+ - NCT06717542Recruiting
Liver tissue analysis to predict transplant success
This study looks at liver tissue before transplantation to find ways to predict how well the transplant will work. It involves a special treatment called HOPE to help preserve the liver.
BolognaAges 18 years+ - NCT07589985Recruiting
Hepatitis B and Liver Health Study in Zambia
This research study follows people with hepatitis B (a liver infection) in Zambia to understand how their bodies respond to treatment and what happens to the virus over time. It includes people with hepatitis B alone, those also living with HIV, and those whose hepatitis B has cleared.
LusakaAges 18 years+ - NCT07563309Recruiting
Testing a new rapid HIV, hepatitis B, and syphilis test
This study evaluates a new rapid blood test that checks for HIV, hepatitis B, and syphilis all at once. Researchers want to make sure the test works well, is easy to use, and gives accurate results.
Johannesburg, GautengAges 18 years+ - NCT07560488RecruitingPhase 2
Immunotherapy and Chemotherapy Combination for Advanced Liver Cancer
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07557251RecruitingPhase 1
Combination immunotherapy for advanced liver cancer with hepatitis B
This trial tests a new combination of three drugs (BRII-5395, sintilimab, and bevacizumab) for advanced hepatocellular carcinoma (liver cancer) in patients with hepatitis B who have not responded well to previous treatments. The goal is to evaluate whether this combination is safe and effective.
BeijingAges 18–70 - NCT07552727Recruiting
Exercise program for fatty liver disease
This study tests whether a structured exercise program can help reduce fat buildup in the liver for people with overweight or obesity and related conditions like insulin resistance or type 2 diabetes. The goal is to see if regular physical activity improves liver health without medication.
Valdivia, Los Ríos RegionAges 18–59 - NCT06742424RecruitingPhase 2
PD-L1 antibody + bevacizumab + liver chemo for advanced liver cancer
This trial tests whether combining a PD-L1 antibody (an immunotherapy) with bevacizumab (a drug that slows blood vessel growth to tumors) and a liver-directed chemotherapy infusion can help people with advanced liver cancer that has spread outside the liver. It is designed for patients who have not previously received these specific treatments.
Chengdu, SichuanAges 18–75 - NCT07542951Enrolling by invitationPhase 4
TAF vs TDF antiviral treatment during pregnancy for hepatitis B
This study compares two antiviral medications (TAF and TDF) in pregnant women with hepatitis B to see which is safer and more effective during pregnancy and for the baby's health.
Guangzhou, GuangdongAges 20–40
Hear when a new Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis?
- Yes. Clin2 currently lists 480 recruiting hepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.